Search

Your search keyword '"Kitamura, Yoshihisa"' showing total 1,180 results
Start Over Author "Kitamura, Yoshihisa"
1,180 results on '"Kitamura, Yoshihisa"'

14. Alpha7 nicotinic acetylcholine receptor-specific agonist DMXBA (GTS-21) attenuates Aβ accumulation through suppression of neuronal γ-secretase activity and promotion of microglial amyloid-β phagocytosis and ameliorates cognitive impairment in a mouse model of Alzheimer's disease

Author

Takata, Kazuyuki, Amamiya, Takahide, Mizoguchi, Hiroaki, Kawanishi, Shohei, Kuroda, Eriko, Kitamura, Risa, Ito, Aina, Saito, Yuki, Tawa, Manami, Nagasawa, Tomofumi, Okamoto, Haruka, Sugino, Yuko, Takegami, Shigehiko, Kitade, Tatsuya, Toda, Yuki, Kem, William R., Kitamura, Yoshihisa, Shimohama, Shun, and Ashihara, Eishi

Published
2018
Full Text
View/download PDF

25. Central and Enteric Neuroprotective Effects by Eucommia ulmoides Extracts on Neurodegeneration in Rotenone-induced Parkinsonian Mouse

Author

Imafuku, Fuminori, Miyazaki, Ikuko, Sun, Jin, Kamimai, Sunao, Shimizu, Takashi, Toyota, Toshiaki, Okamoto, Yusei, Isooka, Nami, Kikuoka, Ryo, Kitamura, Yoshihisa, and Asanuma, Masato

Subjects
glia, Plant Extracts, Dopamine, Dopaminergic Neurons, Eucommiaceae, dopamine neuron, Neurodegenerative Diseases, Antioxidants, Mice, Neuroprotective Agents, Rotenone, Parkinson’s disease, alpha-Synuclein, Animals, Metallothionein, Chlorogenic Acid, Eucommia ulmoides, enteric neuron
Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disease of both the central and peripheral / enteric nervous systems. Oxidative stress and neuroinflammation are associated with the pathogenesis of PD, suggesting that anti-oxidative and anti-inflammatory compounds could be neuroprotective agents for PD. Eucommia ulmoides (EU) is a traditional herbal medicine which exerts neuroprotective effects by anti-inflammatory and anti-oxidative properties. Our previous study showed that treatment with chlorogenic acid, a component of EU, protected against neurodegeneration in the central and enteric nervous systems in a PD model. In this study, we examined the effects of EU extract (EUE) administration on dopaminergic neurodegeneration, glial response and α-synuclein expression in the substantia nigra pars compacta (SNpc), and intestinal enteric neurodegeneration in low-dose rotenone-induced PD model mice. Daily oral administration of EUE ameliorated dopaminergic neurodegeneration and α-synuclein accumulation in the SNpc. EUE treatment inhibited rotenone- induced decreases in the number of total astrocytes and in those expressing the antioxidant molecule metallothionein. EUE also prevented rotenone-induced microglial activation. Furthermore, EUE treatment exerted protective effects against intestinal neuronal loss in the PD model. These results suggest that EU exerts neuroprotective effects in the central and enteric nervous systems of rotenone-induced parkinsonism mice, in part by glial modification.

Published
2022

31. Retrospective Cohort Study of Clinical Efficacy and Safety of Cefozopran for Treating Febrile Neutropenia during Chemotherapy in Patients with Lung Cancer

Author

Higashionna, Tsukasa, Ushio, Soichiro, Esumi, Satoru, Murakawa, Kiminaka, Kitamura, Yoshihisa, and Sendo, Toshiaki

Subjects
lung cancer, Lung Neoplasms, Treatment Outcome, cefozopran, retrospective, Humans, Cefepime, Anti-Bacterial Agents, Cephalosporins, Febrile Neutropenia, Retrospective Studies
Abstract

Febrile neutropenia (FN) is a serious side effect in patients undergoing cancer chemotherapy and frequently proves fatal. Since infection control is crucial in the management of FN, the antimicrobial agent cefozopran (CZOP) has been recommended but not approved for routine use in clinical care of FN in Japan. However, few studies of CZOP in the management of FN have used a thrice daily dose schedule. The aim of this study was to retrospectively compare the efficacy and safety of CZOP at a dose of 1 g three times daily to those of cefepime (CFPM) in the treatment of FN in our lung cancer patients. The response rates of the CZOP and CFPM groups were 89.5% (17/19 cases) and 83.0% (39/47 cases), respectively, with no significant difference between the two groups. The median duration of antimicrobial treatment was 6 days (4-10 days) in the CZOP group and 7 days (3-13 days) in the CFPM group, with no significant difference between groups. The incidence rates of adverse events were 21.1% (4/19 cases) in the CZOP group and 19.1% (9/47 cases) in the CFPM group. No adverse events of Grade 3 or higher were observed in either group. The findings of the present study suggest that CZOP administration at a dose of 1 g three times per day as an antimicrobial treatment alternative against FN.

Published
2022

32. Anxiolytic-like effects of hochuekkito in lipopolysaccharide-treated mice involve interleukin-6 inhibition

Author

Ushio, Soichiro, Wada, Yudai, Nakamura, Mizuki, Matsumoto, Daiki, Hoshika, Kota, Shiromizu, Shoya, Iwata, Naohiro, Esumi, Satoru, Kajizono, Makoto, Kitamura, Yoshihisa, Sendo, Toshiaki, Ushio, Soichiro, Wada, Yudai, Nakamura, Mizuki, Matsumoto, Daiki, Hoshika, Kota, Shiromizu, Shoya, Iwata, Naohiro, Esumi, Satoru, Kajizono, Makoto, Kitamura, Yoshihisa, and Sendo, Toshiaki

Abstract

Hochuekkito (HET) is a Kampo medicine used to treat postoperative and post-illness general malaise and decreased motivation. HET is known to regulate immunity and modulate inflammation. However, the precise mechanism and effects of HET on inflammation-induced central nervous system disorders remain unclear. This study aimed to assess the effect of HET on inflammation-induced anxiety-like behavior and the mechanism underlying anxiety-like behavior induced by lipopolysaccharide (LPS). Institute of Cancer Research mice were treated with LPS (300 mu g/kg, intraperitoneally), a bacterial endotoxin, to induce systemic inflammation. The mice were administered HET (1.0 g/kg, orally) once a day for 2 weeks before LPS treatment. The light-dark box test and the hole-board test were performed 24 h after the LPS injection to evaluate the effects of HET on anxiety-like behaviors. Serum samples were obtained at 2, 5, and 24 h after LPS injection, and interleukin-6 (IL-6) levels in serum were measured. Human and mouse macrophage cells (THP-1 and RAW264.7 cells, respectively) were used to investigate the effect of HET on LPS-induced IL-6 secretion. The repeated administration of HET prevented anxiety-like behavior and decreased serum IL-6 levels in LPS-treated mice. HET significantly suppressed LPS-induced IL-6 secretion in RAW264.7 and THP-1 cells. Similarly, glycyrrhizin, one of the chemical constituents of HET, suppressed LPS-induced anxiety-like behaviors. Our study revealed that HET ameliorated LPS-induced anxiety-like behavior and inhibited IL-6 release in vivo and in vitro. Therefore, we postulate that HET may be useful against inflammation-induced anxiety-like behavior.

Published
2022

45. Mirtazapine suppresses dopamine neurodegeneration by inducing metallothionein expression via stimulation on serotonin 1A receptor of astrocyte.

Author

Ryo, Kikuoka, primary, Miyazaki, Ikuko, additional, Kubota, Natsuki, additional, Maeda, Megumi, additional, Kagawa, Daiki, additional, Moriyama, Masaaki, additional, Sato, Asuka, additional, Murakami, Shinki, additional, Kitamura, Yoshihisa, additional, Sendo, Toshiaki, additional, Zamami, Yoshito, additional, and Asanuma, Masato, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results